The past decade has witnessed tremendous therapeutic progress in the targeting of ER+, PR+, or Her2+ breast cancers, but the therapeutic strategies targeting TNBC human breast cancer are still insufficient [3,4]. This evidence concerns the gene PGR and breast carcinoma.